Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer

BJU International

Volumn 114, Issue 2, 2014, Pages 168-176

  Nguyen, Daniel P ^b,c   Li, Jinyi ^a   Yadav, Shalini S ^a   Tewari, Ashutosh K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

apoptosis; castration resistant; IKK ; inflammation; metastasis; NF B; prostate cancer

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ANDROGEN RECEPTOR; BORTEZOMIB; CARFILZOMIB; DOCETAXEL; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IXAZOMIB; IXAZOMIB CITRATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SALINOSPORAMIDE A;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BONE METASTASIS; CANCER RESISTANCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DISEASE SPECIFIC SURVIVAL; GLEASON SCORE; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

APOPTOSIS; CASTRATION-RESISTANT; IKK-Α; INFLAMMATION; METASTASIS; NF-ΚB; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; INFLAMMATION; MALE; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84905095813     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12488     Document Type: Review

References (56)

1. Virchow R,. Die krankhaften Geschwülste. Vorlesungen über Pathologie, Wintersemester 1862-1863, Universität zu Berlin. Verlag von August Hirschwald, Berlin, 1864-1865. Available at: http://books.google.com. Accessed 1 March 2013
2. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
3. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899
4. Gueron G, De Siervi A, Vazquez E,. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 2012; 15: 213-221
5. Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4 + lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008; 68: 1-10
6. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF,. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med 2012; 90: 1343-1355
7. Pahl HL,. Activators and target genes of Rel/NF-kB transcription factors. Oncogene 1999; 18: 6853-6866
8. Ghosh S, Karin M,. Missing pieces in the NF-κB puzzle. Cell 2002; 109: S81-96
9. Sun SC,. The noncanonical NF-κB pathway. Immunol Rev 2012; 246: 125-140
10. Gasparian AV, Yao YJ, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115: 141-151
11. Shukla S, MacLennan GT, Marengo SR, Resnick MI, Gupta S,. Constitutive activation of PI3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005; 64: 224-239
12. De Angulo A, Faris R, Cavazos D, Jolly C, Daniel B, DeGraffenried L,. Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis. Prostate 2013; 73: 855-864
13. Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F,. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004; 10: 8460-8464
14. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390-400
15. McCall P, Bennett L, Ahmad I, et al. NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer 2012; 107: 1554-1563
16. Ismail HA, Lessard L, Mes-Masson AM, Saad F,. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 2004; 58: 308-313
17. Wong CP, Bray TM, Ho E,. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett 2009; 276: 38-46
18. Rodriguez-Berriguete G, Prieto A, Fraile B, et al. Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 2010; 21: 241-250
19. Shukla S, Gupta S,. Suppression of constitutive and tumor necrosis factor α-induced nuclear factor NF-κB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-κB-responsive genes. Clin Cancer Res 2004; 10: 3169-3178
20. Xu Y, Josson S, Fang F, et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 2009; 69: 3267-3271
21. Catz SD, Johnson JL,. Transcriptional regulation of bcl-2 by nuclear factor kB and its significance in prostate cancer. Oncogene 2001; 20: 7342-7351
22. Guo F, Kang S, Zhou P, Guo L, Ma L, Hou J,. Maspin expression is regulated by the non-canonical NF-κB subunit in androgen-insensitive prostate cancer cell lines. Mol Immunol 2011; 49: 8-17
23. Mahadevan NR, Rodvold J, Almanza G, Pérez AF, Wheeler MC, Zanetti M,. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer 2011; 11: 229
24. Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006; 25: 387-398
25. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM,. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001; 61: 7255-7263
26. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM,. Par-4, a proapoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1: 152-160
27. Codony-Servat J, Marin-Aguilera M, Visa L, et al. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate 2013; 73: 512-521
28. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ,. Blockade of NF-kB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-4197
29. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC,. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005; 65: 9891-9898
30. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837
31. Killian PH, Kronski E, Michalik KM, et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 2012; 33: 2507-2519
32. Longoni N, Sarti M, Albino D, et al. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression. Cancer Res 2013; 73: 4533-4547
33. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B,. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009; 28: 3573-3585
34. Andela VB, Gordon AH, Zotalis G, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003; 415: S75-85
35. Jin R, Sterling JA, Edwards JR, Degraff DJ, et al. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One 2013; 8: e60983
36. Graham TR, Odero-Marah VA, Chung LW, Agrawal KC, Davis R, Abdel-Mageed AB,. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate 2009; 69: 168-180
37. Nelius T, Filleur S, Yemelyanov A, et al. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007; 121: 999-1008
38. Ko S, Shi L, Kim S, Song CS, Chatterjee B,. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol 2008; 22: 273-286
39. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-849
40. Jin RJ, Lho Y, Connelly L, et al. The nuclear factor-kappaB pathways controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762-6769
41. Zhang L, Altuwaijri S, Deng F, et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175: 489-499
42. Nadiminty N, Lou W, Sun M, et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010; 70: 3309-3319
43. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC,. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008; 68: 1725-1733
44. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52: 183-200
45. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446: 690-694
46. Ammirante M, Luo J, Grivennikov S, Nedospasov S, Karin M,. B-cell derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305
47. Ammirante M, Kuraishy AI, Shalapour S, et al. An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 2013; 27: 1435-1440
48. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T,. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-κB. Cell 1994; 78: 773-785
49. Herndon T, Deisseroth AB, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 4559-4563
50. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ,. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2: 835-843
51. Morris MJ, Kelly WK, Slovin S, et al. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 2007; 178: 2378-2383
52. Hainsworth JD, Meluch AA, Spigel DR, et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer 2007; 5: 278-283
53. Kraft AS, Garrett-Mayer E, Wahlquist AE, et al. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther 2011; 12: 119-124
54. Wright JJ,. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16: 4094-4104
55. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-1980
56. Jain G, Voogdt C, Tobias A, et al. IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia 2012; 14: 178-189